Phio Pharmaceuticals Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.3M
- Price
- $1.18
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.48%
- Volume
- 138.3K
About
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Quick stats
Shares outstanding11.6M
Computed float11.6M
Float / shares99.5%
Cash runway (months)9.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001533040
Websitehttps://www.phiopharma.com
AI Summary
AI-generated1/35
minorbullishoperations update
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
Phio Pharmaceuticals received a U.S. Notice of Allowance for a patent covering PH-894, an INTASYL compound designed to selectively silence the BRD4 protein associated with proliferative and infectious diseases.
This milestone strengthens the company's intellectual property estate, which now includes 54 issued patents covering its gene-silencing technology, specific gene targets and therapeutic applications.
CEO Robert Bitterman stated that the patent solidifies the commitment to advance PH-894 in the U.S. and pursue strategic collaborations, while the company continues its Phase 1b trial of lead asset PH-762 for skin cancers.